pembrolizumab
merck
['hncsm', 'keynote-412', 'head and neck', 'pembro']
#esmo22 highlights: primary results of the phase 3 keynote-412 study: pembrolizumab with chemoradiation therapy vs placebo plus crt for locally advanced head and neck squamous cell carcinoma with jean-pascal machiels. #hnscc #hncsm
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.